Please login to the form below
epigenetics
This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.
Merck to acquire Imago BioSciences in deal worth $1.35bn
LSD1, also called KDM1A, is a member of a group of epigenetic proteins that regulate gene expression through chemical modifications of proteins, RNA and DNA.
Latest news
-
ICR study reveals how cancers can evolve without relying on DNA mutations
The researchers found that epigenetic changes play a key role in how cancers adapt and evolve. ... In the first paper, the researchers collected 1, 373 samples from 30 bowel cancers and looked at epigenetic changes as cancers evolved.
-
STORM Therapeutics receives Innovate UK grant
STORM Therapeutics, a University of Cambridge spin-out specialising on small molecule therapies targeting RNA epigenetic mechanisms, has been awarded a Biomedical Catalyst grant by Innovate UK. ... Founded in 2015 by Professors Tony Kouzarides and Eric
-
MorphoSys expands oncology pipeline with $1.7bn acquisition of Constellation Pharmaceuticals
German biopharma company MorphoSys has announced that it will acquire Constellations Pharmaceuticals, a clinical-stage company with expertise in epigenetics, for a total of $1.7bn. ... We are proud that MorphoSys has recognised the strength of our team,
-
UK scientists begin testing BCG vaccine for severe COVID-19 protection
In the same article, the authors added that the BCG vaccine induces metabolic and epigenetic changes that enhance innate immune response to subsequent infections in a process called ‘trained immunity’.
-
BMS’ oral maintenance therapy boosts survival in AML patients
We are extremely encouraged by the results of the QUAZAR AML-001 study as a part of our continuing commitment to both epigenetic research and myeloid diseases,” said Samit Hariwat, chief
More from news
Approximately 2 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
The expansion of Alzheimer’s R&D is underpinned by evidence that the disease has a range of drivers, including Abeta, inflammation and epigenetics, that evolve as it progresses. ... And a host of other academic and industry teams are looking at
-
Deal Watch November 2016
licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.
-
Deal Watch January 2016
Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research
-
Deal Watch October 2015
Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).
-
Pharma deals in August 2015
This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
ICR appoints Kristian Helin as its new chief executive
Epigenetics Research.
-
Professor Thomas Cech joins Storm Therapeutics
mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.
-
Storm Therapeutics bolsters its team
As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,
-
Storm Therapeutics strengthens its board
RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.
-
Rubius Therapeutics strengthens senior team
He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing
More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- Eli Lilly announces $450m investment in US manufacturing site
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- Sandoz’s high concentration Hyrimoz formulation recommended for use in EU
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- GSK to submit drug application for new antibiotic to US FDA
- EU outlines measures to mitigate antibiotic shortage across Europe
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
